Versant Venture Capital VI, L.P.
CIK 1687880 · last filed 2025-08-26
Versant Venture Capital VI, L.P. is a corporate insider who has filed 27 SEC Form 4 insider transactions across 7 companies since 2019. The most recent filing shows the insider sold $66.8M of LENZ on Aug 26, 2025. Across all open-market trades the lifetime net is −$98.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $44.7M across reported positions. The firm reports its address in San Francisco, CA. 58 SEC filings were submitted jointly with Versant Ventures VI GP, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$44.72M
7
27
-$98.34M
Filer Profile
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ | 10%+ Owner | 2,299,292 | $4.52 | $10.39M | -$216.73M | 3 | 2025-08-26 |
| IPSC | 10%+ Owner | 13,259,905 | $1.94 | $25.72M | $0 | 1 | 2021-12-28 |
| LENZ Therapeutics, Inc. (GRPH) Delisted | 10%+ Owner | 2,319,446 | $22.26 | $51.63M | $18.36M | 1 | 2021-07-01 |
| BDTX | 10%+ Owner | 4,343,210 | $1.98 | $8.60M | $39.27M | 9 | 2020-11-25 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 3,754,051 | $60.05 | $225.43M | $0 | 1 | 2020-07-21 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 7,297,318 | $54.65 | $398.80M | -$24.20M | 8 | 2020-07-10 |
| Oyster Point Pharma, Inc. (OYST) Delisted | 10%+ Owner | 2,945,158 | $11.17 | $32.90M | $84.96M | 1 | 2019-11-04 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-26 | LENZ | Sell (S) | −1,692,846 | -$66.82M | EDGAR |
| 2025-07-14 | LENZ | Sell (S) | −1,722,384 | -$58.56M | EDGAR |
| 2025-06-12 | LENZ | Sell (S) | −3,150,000 | -$91.35M | EDGAR |
| 2024-08-13 | TPST | Notice (144) | −387,999 | -$427.0K | EDGAR |
| 2024-08-09 | TPST | Notice (144) | −400,000 | -$7.21M | EDGAR |
| 2024-03-25 | — | Other (J) | +5,383,827 | $0 | |
| 2021-12-28 | IPSC | Other (J) | −2,226,024 | $0 | EDGAR |
| 2021-07-01 | LENZ Therapeutics, Inc. (GRPH) Delisted | Mixed | +84,308,676 | $18.36M | EDGAR |
| 2020-11-25 | BDTX | Other (J) | −3,047,652 | $0 | EDGAR |
| 2020-11-23 | BDTX | Sell (S) | −520,068 | -$17.17M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.